FDA’s new AI labeling push could change how patients and clinicians judge medical devices

The FDA is pushing for clearer labeling of AI-enabled medical devices and software, with a particular focus on cardiac tools. For patients and families, that could make it easier to tell what an AI system does, how it is supervised, and how much evidence supports its use.

For clinicians, the shift is also a reminder that the label is part of the safety picture. In plain language, the FDA wants disclosure that helps users judge the device’s purpose, oversight, and known performance.

Why the FDA is focusing on labeling

At a January 27, 2026 FDA presentation, researchers described how patients and clinicians react more positively when labels explain regulatory approval, device performance, provider oversight, and the added value of AI. The agency said the work reflects a broader need for transparency and trust in AI- and machine-learning-enabled cardiac devices and software.

That matters because many people assume a device is either “approved” or not, without understanding the details of how AI fits into care. The FDA’s message is that the label should help close that gap.

What FDA says users should be able to see

The FDA’s AI-enabled medical devices page says its list is meant to help identify devices authorized for marketing in the United States and to improve transparency for providers and patients. The list includes devices that have met the agency’s applicable premarket requirements and have publicly available summaries of safety and effectiveness.

The agency also notes that the list is not complete. It is based mainly on AI-related terms used in public summaries and classifications, so it may not capture every AI-enabled product. FDA says it is also exploring ways to identify devices that use foundation models, including large language models and multimodal systems.

Why disclosure matters

Disclosure is not just a paperwork issue. A JAMA commentary on AI disclosure and patient consent argues that patients may want to know when AI is involved in their care. That is especially important when the device is helping guide decisions that affect diagnosis, monitoring, or treatment planning.

Clearer disclosure can also help people ask better questions about evidence, oversight, and limits. If a product relies on AI, readers should know whether a clinician is reviewing its output, whether the system is meant to assist rather than replace judgment, and what is known about the situations where it works best.

What FDA is doing beyond labels

The labeling effort is only one part of the agency’s work. FDA is also building an AI-enabled medical device list and asking for public comment on how to measure performance in the real world after a product is deployed.

That real-world question is important because an AI system can behave differently over time as clinical practice, patient populations, workflow, and data inputs change. FDA said it is especially interested in performance drift, meaning the possibility that a system becomes less reliable after it is in use.

What readers can ask before using an AI-enabled device

What does the AI part of this device actually do?
Is a clinician reviewing the result, or is the tool acting on its own?
Has the device been authorized, cleared, or approved by FDA?
What evidence supports its use for this specific purpose?
Are there known limits, such as certain patients, settings, or data inputs where performance is weaker?
How is the device monitored after it is in use?

What remains uncertain

FDA’s direction is clear, but the details are still evolving. It is not yet settled how standardized AI disclosures will become across products, or how consistently real-world monitoring will be implemented. The agency’s public comment process suggests those questions are still being worked out.

For everyday readers, the practical takeaway is straightforward: if a medical device says it uses AI, the most useful next step is to ask for a plain-language explanation of what it does, who oversees it, and what evidence supports it.

That kind of transparency does not answer every question, but it can make AI-enabled care easier to judge, safer to use, and less confusing for patients and families.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.